No matter how the market flourishes or how promising a technology’s outlook, there’s still one thing that can bring even the most high-flying genomics execs to their knees. It’s the US FDA, headed up by Bernard Schwetz, acting principal deputy commissioner. His years of toxicology research experience have prepared him for what may be the coming onslaught of genomics-based drugs. He recently agreed to an e-mail interview with GT’s Meredith Salisbury.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.